The Next Obesity Bet Lies Deep Inside Cells

As GLP-1 drugs dominate obesity care, a handful of biotechs are probing mitochondria, searching for new metabolic levers inside the cell

17 Dec 2025

For more than a decade, obesity drug research has chased the same goal, quite the appetite. Hormones that signal fullness, especially GLP-1s, have reshaped the market and expectations alike. Now, a smaller and quieter shift is taking place. Some biotechs are looking past the gut and into the cell, asking whether weight can be managed by changing how energy is made and burned.

The idea gained notice late last year when Pretzel Therapeutics shared preclinical data on a mitochondrial target known as POLRMT. At a major US obesity meeting, the company reported improvements in weight, blood sugar control, and energy expenditure in animal models. The work is still early, with no human trials underway. Even so, it stood out in a field eager for fresh thinking.

This is not a challenge to GLP-1 drugs. Those therapies continue to dominate investment and clinical momentum. Instead, mitochondrial research is being framed as a complement. Rather than reducing food intake, the aim is to improve how efficiently cells use energy. For patients who do not respond well to hormone-based drugs, or who struggle with side effects, that difference could matter.

Market timing helps explain the interest. Demand for obesity treatments has surged, drawing in large pharmaceutical companies and turning GLP-1s into one of biopharma’s most crowded arenas. Roche and others have committed billions to hormone-driven platforms. In such a packed landscape, alternative biology offers a longer-term hedge.

“This is about opening an additional lane,” said one industry analyst. “When a single class dominates, companies start exploring adjacent mechanisms that could eventually work alongside it.”

The appeal is not just scientific. Novel targets create new options for partnerships, acquisitions, and pipeline planning. For smaller biotechs, a differentiated preclinical program can spark strategic interest. For larger companies, it offers flexibility as competition and pricing pressure grow.

The risks remain substantial. Mitochondria sit at the heart of cellular life, so safety and durability will face intense scrutiny as programs advance. Still, early signals suggest that controlling cellular energy could widen the metabolic playbook. Obesity innovation is no longer confined to the gut-brain axis, and mitochondria are starting to earn a place in the conversation.